Capabilities by Region: United States
Greenhill has considerable advisory experience in the United States. Our Managing Directors and professionals have advised clients on transactions involving many of the leading companies in the region and have access to a vast network of corporate relationships throughout United States.
Greenhill established its presence in the United States in January 1996 with the opening of our office in New York. Greenhill further expanded its U.S. presence with the opening of Chicago and San Francisco offices in 2008 and the Houston office in 2009.
For more information on Greenhill’s advisory practice in the United States and our capabilities in the region, please contact Chief Executive Officer Scott Bok or President Kevin Costantino in our New York office.
Below we highlight a few of the transactions on which we have advised in this region:
Recent Transactions
Sort By
Retail Propane Operations of Inergy, L.P.
Advised Inergy, L.P., a master limited partnership with propane and midstream natural gas operations, on the sale of its retail propane operations to Suburban Propane Partners, L.P., a national propane retailer
Flow Control Business of Tyco International Ltd.
Provided fairness opinion to the Board of Directors of Pentair, Inc. in connection with its all-stock merger with Tyco Flow Control, a division of Tyco International Ltd. (+Transaction value represents enterprise value of combined entity)
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
Advantage Resourcing America, Inc. & Advantage Resourcing Europe B.V.
Advised Recruit Co. Ltd, a leading staffing and publishing company in Japan, on the acquisition of all outstanding shares of Advantage Resourcing America, Inc. & Advantage Resourcing Europe B.V, wholly owned by investment vehicles affiliated with Cerberus Capital Management L.P.
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives